PropThink: Intermezzo Sales Still Slow, but Expansion Efforts Are Underway

[ACN Newswire] – By Jake KingIntermezzo prescriptions are slowly growing , says Transcept management, but royalty revenue has yet to make a substantial contribution to Transcept Pharmaceuticals’ (NASDAQ:TSPT) top-line. … more

View todays social media effects on TSPT

View the latest stocks trending across Twitter. Click to view dashboard